Why PG, JNJ, and KO Could Surprise Investors Next Year

Quick Read

• PG and JNJ people $180 and $300 respectively, with JNJ's oncology pipeline posting cause maturation up to 83% successful Q1.

• KO's FIFA World Cup 2026 activation crossed 180+ markets, paired with Zero Sugar measurement up 16%, builds the lawsuit for $100.

• It sounds nuts, but SoFi1 is giving caller Active Invest users up to $3,000 successful banal for a constricted time, and each it takes is simply a $50 deposit to get started.2 See for yourself (Sponsor)

Defensive bluish chips seldom predominate headlines, but heading into 2027, 3 of the market's astir reliable dividend payers basal retired arsenic durable compounders.

With user sentiment astatine recessionary levels of 49.5 and shoppers trading down, staples and healthcare names are gaining relevance. Let's locomotion done however Procter & Gamble (NYSE:PG), Johnson & Johnson (NYSE:JNJ), and Coca-Cola (NYSE:KO) could scope $180, $300, and $100 respectively successful 2027.

Where Wall Street Sees These Names Today

PG trades astatine $146.97, up 4.8% year-to-date, with analysts targeting $160.70. JNJ is simply a 2026 outperformer, climbing 25.56% year-to-date to $256.98, with the Street eyeing $271.73. KO has done adjacent better, gaining 25.9% YTD to $86.85, with a statement people of $94.70. Our targets beryllium supra each consensus.

Procter & Gamble: The Path to $180

PG trades adjacent 22x earnings, successful enactment with the market. At $180, that aggregate would agelong to astir 26x FY2027 guidance midpoint of $7, a premium justified by 70 consecutive years of dividend increases. FY2026 delivered gross of $87.03B (+3.26%) and escaped currency travel of $15.84B (+12.74%).

CEO Shailesh Jejurikar told shareowners PG is "building momentum with consumers" and is "confident successful our plans to accelerate maturation from semester-to-semester."

With Beauty increasing 6% successful Q4, a 5th consecutive EPS beat, and insider buying, a re-rating toward $180 is achievable if the promised productivity programme offsets the $1B commodity headwind.

SoFi Active Invest is offering a limited-time promotion. Open an account, money it with $50 oregon more, and you could person up to $3,000 successful complimentary banal for Active Invest accounts. See for yourself by clicking present now. (Sponsor)

Johnson & Johnson: The Path to $300

JNJ needs astir 17% much upside to deed $300. Management raised FY2026 guidance to $100.3B-$101.3B gross and adjusted EPS of $11.45-$11.65. At $300, JNJ would commercialized astir 26x that midpoint, tenable for a institution posting 9.9% Q1 gross growth.

Oncology is the engine: DARZALEX grew 22.5%, TREMFYA jumped 68.3%, and RYBREVANT/LAZCLUZE surged 82.7%. CEO Joaquin Duato called 2025 "a catapult year" with the strongest pipeline successful institution history.